Kornimate/medical-research-clean huggingface dataset:
exploratory investigation of advanced pet/mri metrics for bladder cancer characterization

Conditions: Bladder Cancer

Summary: the overarching goal of this project is to explore whether associations exist between metrics obtained from pet/mri incorporating advanced mri sequences and features of bladder cancer, including grade, stage, and treatment response.

the investigators will assess an advanced non-gaussian diffusion-weighted imaging (dwi) model termed diffusion kurtosis imaging, multi-echo t2 mapping, dynamic contrast-enhanced (dce) mri using a motion-robust high-temporal and high-resolution radial acquisition scheme employing compressed sensing, and simultaneously acquired 18-fluoro (18f)- fluorodeoxygluclose (fdg) data. preliminary data demonstrates the investigators ability to execute and evaluate all of these techniques at the investigators center. the investigators hypothesize that these techniques will be sensitive to functional and metabolic differences between subsets of bladder cancer cases and will improve upon the performance of current imaging protocols in bladder cancer characterization. moreover, the investigators believe that these techniques will provide complementary information, such that they may be combined in a synergistic fashion for bladder cancer evaluation.

Eligibility criteria:
inclusion criteria: * histologic or imaging evidence of urothelial carcinoma of the bladder * age ≥ 18 years of age * if female of childbearing potential, pregnancy test is negative. (in these instances, the patient will need to provide documentation of negative pregnancy test results.) exclusion criteria: * inability to tolerate mri including conditions such as claustrophobia or inability to lay flat for \> 45 minutes. * presence of pacemaker/implantable cardiac device (icd) or perfusion pumps * ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial heart, valves with steel parts, metal fragments, shrapnel, bullets, tattoos near the eye, or steel implants. * substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study

Keywords: bladder cancer mri pet
venous distension in patients with aneurysmatic arterial disease

Conditions: Aortic Aneurysm, Abdominal; Popliteal Artery Aneurysm; Peripheral Arterial Occlusive Disease; Vascular Diseases; Aortic Diseases; Varicose Veins

Summary: the aim of the study is to assess if venous distension in patients with aneurysmatic arteriopathy is higher compared to patients with peripheral arterial occlusive disease (paod) and in controls.

patients with aortic aneurysm and patients with paod and controls will be investigated in the following manner: duplexsonography with assessment of the arterial diameters in the aorta and leg arteries. duplexsonography with assessment of venous reflux in proximal and deep veins of both legs duplexsonography testing of venous distension in the common femoral vein, the great saphenous vein and the femoral vein.

Eligibility criteria:
inclusion criteria: * patients with dilatative arteriopathy (da) the aortic diameter must be \> 3 cm or the popliteal artery diameter \> 1.5 cm * patients with arterial occlusive disease (paod) defined with an ankle brachial index (abi) \< 0.9 and positive criteria in the edinburgh questionnaire * patients able to give informed consent * control group of age matched persons without paod (abi \> 0.9) and without da exclusion criteria: * impossibility to stand * diabetes * no given informed consent * persons and patients \< 18 years old * acute deep venous thrombosis * history of deep venous thrombosis

Keywords: venous distension venous reflux
evaluation of the bunnylens tr intraocular lens

Conditions: Cataract

Summary: with age, a human crystalline lens opacifies (cataract) disabling the eye in generating a clear, well contrasted image. the only therapeutic solution to this problem is surgical replacement of the crystalline lens with an intraocular lens (cataract surgery). in addition to the cataract, the person might suffer from pre-existing cormeal astigmatism. in cases of severe corneal astigmatism, the standard iol might not provide the optimal result, and additional surgical procedures as incisional keratotomy or limbal relaxing incisions might be required. bunnylens tr iol is an aspheric toric intraocular lens providing a precise, superior alternative to surgical treatment of pre-existing corneal astigmatism. the bunnylens tr iol is designed for micro-incision cataract surgery (mics), through 1.8mm incisions. the aims of this study are to: * demonstrate a reduction in refractive cylinder compared to pre-operative corneal astigmatism * exceed monocular best corrected distance visual acuity results provided in iso guidelines.

the reduction in refractive cylinder compared to pre-operative corneal astigmatism will be assessed using pre- and postoperative subjective refraction evaluation. units of the measurement: diopters. monocular best corrected distance visual acuity will be assessed using etdrs charts. units of the measurement: logmar. there are no complications related to the bunnylens tr implantation beyond those that might be expected in standard cataract surgery. the complications will be reported using ocular condition forms included in the crfs.

Eligibility criteria:
inclusion criteria: * between 40 and 80 years of age, of either gender and any race; * have preoperative corneal astigmatism of \>= 2 dpt as determined by iol master keratometry; * have regular, bowtie shaped corneal astigmatism. corneal topography printout should be approved and signed by cornea specialist. * anterior chamber depth is between 2.5 to 3.8 mm * axial length is between 22 to 26 mm * are willing and able to understand and sign an informed consent; * have age related cataracts that require extraction followed by implantation of a posterior chamber intraocular lens (iol) and used as an on-label procedure; * are able to obtain pupil dilation \>=4.0 mm. exclusion criteria: * following disease(s)/condition(s): choroidal hemorrhage, chronic severe uveitis, concomitant severe eye disease, microphthalmos, proliferative diabetic retinopathy, corneal dystrophy, optic nerve atrophy, uncontrolled glaucoma or glaucoma treated by 3 or more medications, uncontrolled systemic disease or any ocular condition, that by opinion of investigator would compromise the refractive outcome or potential of the eye to achieve good vision. * high intraocular pressure (above 25mmhg) * previous intraocular or corneal surgery; * corneal abnormality that would prevent stable and reliable visual acuity and refractive measures; * current rigid contact lens usage (within 3 months prior to the preoperative biometry reading)

Keywords: cataract cataract surgery intaocular lens toric lens
a study to evaluate the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adults with hodgkin and non-hodgkin lymphoma

Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease

Summary: the purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical hodgkin lymphoma and non-hodgkin lymphoma.


Eligibility criteria:
inclusion criteria: * participants with pathologically confirmed high-risk r/r chl, after non-response to or failure of 1or more lines of standard therapy. * participants with pathologically confirmed r/r nhl after non-response to or failure of 1or more lines of standard therapy, including, but not limited to, r/r primary mediastinal b-cell lymphoma, diffuse large b-cell lymphoma (dlbcl), mediastinal gray zone lymphoma (mgzl), anaplastic large cell lymphoma (alcl), or peripheral t-cell lymphoma (ptcl). * participants with pathologically confirmed r/r nhl after non-response to or failure of 2 or more lines of standard therapy, including burkitt lymphoma (blast count \<25% malignant burkitt cells and/or per the investigator's clinical assessment of risk status), lymphoblastic lymphoma (blast count \< 25% of marrow nucleated cells and/or per the investigator's clinical assessment of risk status), nk/t-cell lymphoma (nasal and non-nasal nk/t-cell lymphoma subtypes, but not aggressive nk/t-cell leukemia/lymphoma subtype). * the participant's current disease state must be r/r to standard therapy. * participants must have measurable pet positive disease in both chl and nhl cohorts. exclusion criteria: * primary cns lymphoma of the brain or spinal cord, and secondary cns lymphoma (ie, from systemic non-hodgkin lymphoma) involving the brain, spinal cord, or with leptomeningeal seeding. * prior treatment with an anti-cytotoxic t-lymphocyte-associated protein 4 (anti-ctla-4) antibody, or any other antibody or drug specifically targeting t-cell co-stimulation or checkpoint pathways, with the exception of anti-pd(l)-1 targeted therapies. * prior treatment with lymphocyte activation gene-3 (lag-3)-targeted agents. * participants with clinically significant systemic illnesses unrelated to the cancer as judged by the investigators, which would compromise the participant's ability to tolerate the study treatment. * participants with autoimmune disease. * prior allogeneic bone marrow transplantation. other protocol-defined inclusion/exclusion criteria apply

Keywords: pediatric lymphoma, non-hodgkin hodgkin disease relatlimab nivolumab lymphocyte activation gene-3 lymphoma, large b-cell, diffuse primary mediastinal b-cell lymphoma lymphoma, large-cell, anaplastic burkitt lymphoma lymphoblastic lymphoma nk/ t-cell lymphoma peripheral t-cell lymphoma
key interventions to improve the follow-up adherence post cervical precancerous lesion treatment in ethiopia

Conditions: Suspicious Cervical Cancer Lesions Follow up Adherence

Summary: the goal of this pragmatic randomized control trial is to evaluate the effectiveness of three interventions in improving follow-up adherence among women treated for suspicious cervical lesions in primary healthcare settings in ethiopia. the interventions include structured nurse-led telephone call reminders, home-visit reminders led by health extension workers, and application-based automated sms text reminders. the main questions it aims to answer are: * does structured nurse-led telephone call reminders improve follow-up adherence among women treated for suspicious cervical lesions compared to standard care? * does home-reminder visits led by a health extension worker (hew) improve follow-up adherence among women treated for suspicious cervical lesions compared to standard care? * does app-based automated sms reminders improve follow-up adherence among women treated for suspicious cervical lesions compared to standard care? structured nurse-led telephone call reminders * participants will receive proactive phone call reminders for scheduled follow-up visits. * the intervention includes three rounds: initially at 4 months post-recruitment, then every 4 months for hiv-negative women over a year, and every 2 months for 6 months for women living with hiv. home-reminder visits led by hew health extension workers (hews) will conduct door-to-door visits to remind participants of their scheduled follow-up appointments. • door-to-door visits will occur initially at 4 months (for hiv-negative women) and 2 months (for hiv-positive women) post-recruitment, then every 2 months for 6 months for hiv-positive and every 4 months for 12 months for hiv-negative participants. app-based automated sms reminders * participants will receive sms-based reminders for their follow-up visits. * the intervention consists of three rounds: initial texts at 4 months and 2 months post-recruitment for hiv-negative and hiv-positive women, respectively, followed by reminders every 2 months for 6 months for hiv-positive women and every 4 months for 12 months for hiv-negative women.


Eligibility criteria:
inclusion criteria: * women aged 30-49 (hiv-negative). * women over 25 (hiv-positive). * treated for suspicious cervical lesions after a positive via screening. exclusion criteria: * history of hysterectomy. * diagnosis of other histological invasive cervical cancer. * suspicious cervical cancer cases. * pregnancy. * prior screening history. * vaginal bleeding. * lack of consent.
psychometric validation of an oral health-related scale for quality of life and coping in people with schizophrenia

Conditions: Schizophrenia

Summary: schizophrenia is a severe and persistent psychological disorder affecting 0.7 to 1% of the world's population and 600,000 people in france. schizophrenic patients are exposed to excess mortality and a life expectancy that is 10 to 15 years lower than the general population (excluding causes of suicide) and to numerous co-morbidities, including oral diseases. to improve this public health problem, concrete action must be undertaken and evaluated in both quantitative and qualitative terms. while there are many quantitative indicators, there are no reliable and valid tools for the perceived oral health of these individuals in the context of their real and/or imagined world. the results of a qualitative study previously carried out by our team (quality study: nct02730832) made it possible to develop two hypothetical questionnaires for evaluating quality of life related to oral health, the schizophrenia oral health profile (sohp), and a questionnaire for evaluating coping strategies with regard to oral health, the schizophrenia coping oral health profile (scoohp). however, before these questionnaires can be used in clinical practice, their psychometric properties must be validated.


Eligibility criteria:
inclusion criteria: * adult person, * patients for whom a diagnosis of schizophrenia is defined according to icd 10 * person who has given his or her oral agreement to participate in the study, with the agreement of the tutor in the context of a tutorship, * managed in a specialised institution (university hospital, psychiatric hospital or hospital), either in full hospitalisation or on an outpatient basis, * fluent use of the french language. exclusion criteria: * psychiatrically unstable and delusional patients. * patients with cognitive abilities too impaired to participate in the study * individuals with no natural teeth * pregnant or breastfeeding women * patients not affiliated to the national health insurance system.
vascular effects of attention deficit hyperactivity disorder (adhd) medications in youth

Conditions: ADHD

Summary: 4.4 million children and adolescents in the united states have been diagnosed with attention deficit hyperactivity disorder (adhd) and more than half are treated with medication. most adhd medications are stimulants, which activate the sympathetic nervous system (sns). sns activation is closely associated with vascular functional and mechanical abnormalities. therefore, adhd medications, via instigating sns activation and altering the hemodynamic profile, may have untoward effects on the vasculature and increase risk of developing cardiovascular disease in children and adolescents who use them. our overall objective in this study is to determine whether adhd medication use is associated sns activation, endothelial dysfunction, and arterial stiffness in children and adolescents. we will address this objective by conducting a case-control study and obtain non-invasive measures of sns activation, endothelial function, and arterial stiffness in children and adolescents (8-17 years old) with (using stimulant medication) and without adhd.

specific aims and hypotheses our overall objective in this study is to determine whether adhd medication use is associated sns activation, endothelial dysfunction, and arterial stiffness in children and adolescents. our hypothesis is: children and adolescents taking adhd medications will have higher sns activation, lower digital reactive hyperemia, and higher pulse wave velocity and aortic augmentation index compared to sibling controls without adhd. study design we will obtain non-invasive measures of sns activation (heart rate variability), endothelial function (digital reactive hyperemia and brachial artery flow-mediated dilation), and arterial stiffness (carotid-radial pulse wave velocity; aortic augmentation index) in youth taking adhd stimulant medication and in their healthy siblings without adhd. study visits will be conducted at the clinical and translational science institute (ctsi) at the university of minnesota. all vascular testing will occur in the vascular biology laboratory within the ctsi.

Eligibility criteria:
inclusion criteria: * age 6-18 years old * current use of adhd stimulant drug therapy limited to methylphenidates or amphetamines * sibling without adhd between the ages of 6-18 years old exclusion criteria: • known (diagnosed) cardiac disease

Keywords: adhd
predictive parameters for difficult tracheal intubation identification in thyroid surgery

Conditions: Intubation;Difficult

Summary: intubation manoeuvres in patients undergoing thyroid surgery might be challenging for anesthesiologist. thyroid gland enlargement (goiter) or tissue fibrosis (neoplasms) could alter the physiologic anatomy of upper airways and trachea, resulting in compression or dislocation. we want to evaluate the incidence and identify predictive parameters of difficult intubation in patients undergoing thyroid surgery.

intubation manoeuvres in patients undergoing thyroid surgery might be challenging for anesthesiologist. thyroid gland enlargement (goiter) or tissue fibrosis (neoplasms) could alter the physiologic anatomy of upper airways and trachea, resulting in compression or dislocation. there are few scientific data about airway management and thyroid pathology and the incidence of difficult tracheal intubation in this specific kind of patient is largely variable from 0% to 12.9%. these data have been collected from little statistical samples (from 50 to 326 patients), the results aren't always unanimous and a study evaluating simultaneously all the risk factors for difficult intubation does not exist. we want to evaluate the incidence and identify predictive parameters of difficult intubation in patients undergoing thyroid surgery. during pre-anesthetic assessment the following data will be collected: inter-incisor gap (cm) mallampati test (1;2;3;4) thyromental distance (cm) prognathism (yes; no) neck motility (\ 90°) total body weight (kg) history of difficult tracheal intubation (yes; no) tracheal deviation at chest x-ray (yes; no) neck circumference (cm) mediastinal goiter (yes; no) histologic features (benign; carcinoma) during the post-anesthesia it will be noted down the following: cormack scale (1; 2a; 2b; 3; 4) number of necessary attempts to intubate (1;2;3;...) time from induction to intubation (min) necessity to use advanced airway management devices (frova; glidescope; ambu-scope; fiber-optic; other)

Eligibility criteria:
inclusion criteria: * thyroid surgery exclusion criteria: * \<18 years

Keywords: intubation difficult thyroid
the captivator emr registry

Conditions: Barrett's Esophagus

Summary: to confirm performance of the captivator™ emr device for resection of early neoplasia in barrett's esophagus.


Eligibility criteria:
inclusion criteria: 1. age 18-80 years. 2. barrett's esophagus with a visible abnormality confirmed upon prior endoscopy. a visible abnormality is described as meeting one or more of the following definitions: * lesion is detected as visible based on white light imaging with any macroscopic appearance according to the paris classification and is also endoscopically resectable. * lesion is detected by narrow band imaging (nbi), but without any other specific characteristics for a visible lesion. * lesion is confirmed to contain high grade dysplasia and/or carcinoma upon prior biopsy. 3. subject is scheduled for endoscopic resection of present neoplasia 4. subject is amenable to emr with no suspicion of submucosal invasion, based on the macroscopic appearance and/or endosonography upon earlier endoscopy. 5. subject is taking ppi (proton pump inhibitor) bid (twice daily) 40 mg (or equivalent dosage). 6. subject is willing to participate, fully understands the content of the informed consent form, and signs the informed consent form. exclusion criteria: 1. subject has previously undergone endoscopic therapy for esophageal neoplasia, including (but not limited to) cryospray therapy, laser treatment, photodynamic therapy, endoscopic mucosal resection, radiofrequency ablation, argon plasma coagulation or radiotherapy. 2. presence of esophageal stenosis preventing passage of a therapeutic gastroscope. 3. endoscopically visible scarring by any cause of the intended treatment zone. 4. esophageal varices. 5. subject has known or suspected esophageal perforation. 6. coagulation disorders or anti-coagulant therapy which cannot be discontinued (aspirin allowed).

Keywords: emr eac barrett's neoplasia multiband mucosectomy
the value of monitoring circulating cell dna (ctdna) in pediatric lymphoma: a prospective, multicenter clinical study

Conditions: Lymphoma

Summary: the next-generation sequencing (ngs) based on liquid biopsy has been an emerging technology to identify tumor-specific genetic aberrations in malignant tumors. the tumor tissue (ffpe) and plasma samples from the newly diagnosed pediatric lymphoma patients were collected and sequenced by 475 genes panel before, during and post treatment, to evaluate the significance of the ctdna in efficacy prediction, predicting recurrence or mechanism of resistance to chemotherapy for pediatric lymphoma.

this is a prospective, multi-center, observational cohort study. the tumor tissue (ffpe) and plasma samples (bone marrow or cerebrospinal fluid samples if necessary) from the newly diagnosed patients were collected and sequenced by 475 genes panel before, during and post treatment. collection and analysis the results of ctdna and chemotherapy response, to explore the mutation map of pediatric lymphoma and to evaluate the significance of liquid biopsy for efficacy prediction, predicting recurrence, mechanism of resistance to chemotherapy.

Eligibility criteria:
inclusion criteria: 1. children with pediatric lymphoma (hl and nhl) that met the criteria and required treatment upon histological and pathological diagnosis; 2. age: \< 18 years old; 3. the working status of the eastern cooperative oncology group (ecog) (ps) : 0-2 points; 4. ct/mri measurable lesion was defined as the longest diameter of at least 1 lymph node ≥ 1.5cm, and it was clearly measurable in 2 vertical directions; 5. complete clinical laboratory examination and pathological examination information; 6. patients can be evaluated on time, and the required samples can be obtained throughout the testing process; 7. after the patient is informed of the project, the informed consent signed by the patient or his legal representative is obtained. exclusion criteria: * patients with any of the following items will not be enrolled in this study: 1. incomplete baseline samples (preoperative plasma samples, tissue, bone marrow, cerebrospinal fluid) due to various reasons; 2. the follow-up samples cannot be obtained during the monitoring process; 3. the researcher considered it unsuitable for enrollment.